GO
| HSI1 | 25,143.05 | +580.81 | 306.41B |
| HSCEI1 | 8,381.90 | +245.17 | 93.65B |
| Back Zoom + Zoom - Block Traded | |
|
2026-07-17 16:21:48 JPM released a research report stating that SKB BIO (06990.HK) has seen strong share price performance recently, mainly driven by the antibody-drug conjugate (ADC) sac-TMT targeting trophoblast cell-surface antigen 2 (TROP2). The OptiTROP-Lung06 Phase III clinical trial conducted in China met its primary endpoint, marking the first time that an ADC+PD-1 combination therapy at this stage demonstrated significantly better efficacy than Keytruda plus chemotherapy. In addition, the National Medical Products Administration has granted priority review status to the supplemental new drug application for sac-TMT for TNBC treatment, further reducing regulatory and execution risks. JPM said that, as multiple registration studies conducted by SKB BIO in China achieved positive results and validation of the asset across multiple tumor types increased, clinical risks have been substantially reduced. The broker raised the company's TP from HKD535 to HKD648 and maintained an Overweight rating.(sl/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |